DJIA 17,689.86 -56.12 -0.32%
NASDAQ 5,128.28 -0.50 -0.01%
S&P 500 2,103.84 -4.79 -0.23%
market minute promo

ImmunoGen (NASDAQ: IMGN)

18.02 0.12 (0.67%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

IMGN $18.02 0.67%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $16.97
Previous Close $17.90
Daily Range $16.80 - $18.78
52-Week Range $5.34 - $19.43
Market Cap $1.6B
P/E Ratio -27.54
Dividend (Yield) $0.00 (0.0%)
Volume 961,998
Average Daily Volume 1,318,798
Current FY EPS -$0.70

Sector

Healthcare

Industry

Drug Makers

ImmunoGen (IMGN) Description

ImmunoGen develops cancer therapeutics through its tumor-activated, prodrug technology, which targets antibodies with cancer-killing drugs. Website: http://www.immunogen.com/

News & Commentary Rss Feed

ImmunoGen: Back to a Development-Stage Biotech

With the biotech no longer collecting Kadcyla royalties, the pipeline becomes the focus of the release of quarterly earnings.

ImmunoGen's (IMGN) CEO Dan Junius on Q4 2015 Results - Earnings Call Transcript

ImmunoGen (IMGN) Q2 2015 Results - Earnings Call Webcast

ImmunoGen Is Climbing Higher... Again

ImmunoGen's shares continue to gain ground in the wake of early-stage trial results for its ovarian cancer drug.

ImmunoGen, Inc.'s Shares Jumped Another 15% Today

Immunogen shares continue to advance on the heels of positive trial data last month.

Monday's ETF Movers: XBI, GDX

10 Best Biotech Stocks in the NASDAQ

5 Healthy Stocks in the Top Biotech ETF - ETF News And Commentary

ImmunoGen's IMGN529 for B-Cell Malignancies Demonstrates Synergistic Activity with Rituximab in Prec

ImmunoGen's IMGN529 for B-Cell Malignancies Demonstrates Synergistic Activity with Rituximab in Preclinical Models of Non-Hodgkin Lymphoma

How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer

See More IMGN News...

IMGN's Top Competitors

IMGN $18.02 (0.67%)
Current stock: IMGN
AMGN $176.59 (2.85%)
Current stock: AMGN
GILD $117.86 (-0.03%)
Current stock: GILD
BIIB $318.78 (0.56%)
Current stock: BIIB